A nurse is caring for a client who is taking rifampin. Which of the following findings should the nurse monitor for as an adverse effect of the medication?

A. Monitor the client for hypotension is not specifically required for epoetin alfa administration. Hypotension is not a common adverse effect of this medication.
B. Inject at a 15-degree angle is incorrect. Subcutaneous injections are typically administered at a 45 to 90-degree angle, not 15 degrees.
C. Check the client’s hemoglobin level is essential before administering epoetin alfa. Epoetin alfa stimulates red blood cell production, and monitoring hemoglobin levels helps assess the effectiveness and safety of the treatment.
D. Administer the medication in the deltoid is not the preferred site for subcutaneous injections. Epoetin alfa is usually administered in the abdomen or thigh.

A. Digoxin and levothyroxine. These medications do not typically interact to cause hearing loss. Digoxin is used for heart conditions, and levothyroxine is a thyroid hormone replacement. Their interaction does not pose a risk for ototoxicity.
B. Furosemide and amikacin. This combination is known to cause ototoxicity. Furosemide is a loop diuretic, and amikacin is an aminoglycoside antibiotic. Both drugs have ototoxic potential, and their combined use increases the risk of hearing loss.
C. Losartan and atorvastatin. These medications do not typically interact to cause hearing loss. Losartan is an antihypertensive, and atorvastatin is a cholesterol-lowering agent. Their interaction does not pose a risk for ototoxicity.
D. Propranolol and raloxifene. These medications do not typically interact to cause hearing loss. Propranolol is a beta-blocker, and raloxifene is used for osteoporosis. Their interaction does not pose a risk for ototoxicity.